LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.
LA JOLLA, March 30, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by University of Michigan researchers in the
LA JOLLA, April 27, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company’s board of
First of Two Planned Phase 2 Studies of Tipifarnib LA JOLLA, May 18, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced that the first
LA JOLLA, Calif. , May 27, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the Jefferies 2015 Global Healthcare Conference.
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the 2015 Wedbush PacGrow Healthcare Conference.
LA JOLLA, Calif. , Sept. 16, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced today that its common stock has been approved for quotation
Second of Two Planned Company Sponsored Phase 2 Trials for Tipifarnib LA JOLLA, Calif. , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers,
LA JOLLA, Calif. , Oct. 14, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of directors. "Tom has extensive knowledge and understanding of the healthcare industry," said Troy Wilson
LA JOLLA, Calif. , Oct. 28, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced that it has commenced an underwritten public offering of
